TIGIT and cancer: New IC molecules, including VISTA, TIM-3, LAG-3, TIGIT, programmed cell death ligand 2 (PD-L2), B7H3, BTLA and GITR, have been identified as potential targets for overcoming tumour heterogeneity and resistance, offering potential for more effective cancer immunotherapy [14].